The agreement, which involves a transaction with CVC, a global private markets manager, will see KKR acquire up to 54% of HCG's equity from CVC Asia V at a price of Rs 445 per share. In accordance with the Securities and Exchange Board of India (SEBI) Takeover Regulations, KKR will also conduct an open offer to purchase additional equity shares from public shareholders. Upon completion of the transaction, KKR's total equity stake in HCG is expected to range between 54% and 77%. Dr. BS Ajaikumar, the founder of HCG, will transition to the role of non-executive chairman, where he will focus on driving clinical, academic, and research and development excellence within the organization. The transaction is expected to close by the third quarter of 2025, subject to customary closing conditions and regulatory approvals. Separately, KKR has initiated an open offer to acquire up to 26% of HCG's expanded voting share capital, offering to purchase 3,70,90,327 equity shares at Rs 504.41 per share, for a total consideration of Rs 1870,87,31,842.07. Founded in 1989, HCG is one of India's largest oncology hospital chains. HCG operates 25 medical care centers across 19 cities with best-in-class infrastructure including 2,500 beds, nearly 100 operating theaters and 40 linear accelerator machines (LINACs). Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises rose 22.46% to Rs 6.98 crore in the quarter ended December 2024 as against Rs 5.70 crore during the previous quarter ended December 2023. Sales rose 18.89% to Rs 557.55 crore in the quarter ended December 2024 as against Rs 468.95 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales557.55468.95 19 OPM %15.8516.76 - PBDT53.2255.22 -4 PBT-3.3011.06 PL NP6.985.70 22 Powered by Capital Market - Live

Healthcare Global Enterprises has revised the meeting of the Board of Directors which was scheduled to be held on 13 February 2025. The meeting will now be held on 14 February 2025.Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 13 February 2025.Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises rose 32.57% to Rs 17.99 crore in the quarter ended September 2024 as against Rs 13.57 crore during the previous quarter ended September 2023. Sales rose 13.69% to Rs 552.47 crore in the quarter ended September 2024 as against Rs 485.96 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales552.47485.96 14 OPM %18.5117.41 - PBDT77.3961.13 27 PBT27.6517.92 54 NP17.9913.57 33 Powered by Capital Market - Live

Healthcare Global Enterprises has executed Business Transfer Agreement on 09 November 2024 (BTA), with HCG NCHRI Oncology LLP, a wholly owned subsidiary, for the acquisition of the oncology business of HCG NCHRI Oncology LLP, located at Nagpur, on a slump sale basis. The consideration payable to the Company by the Seller shall not exceed Rs 25 crore, which shall be determined on the effective date of transfer.Powered by Capital Market - Live

Healthcare Global Enterprises will hold a meeting of the Board of Directors of the Company on 9 November 2024.Powered by Capital Market - Live

Healthcare Global Enterprises announced that the Annual General Meeting (AGM) of the company will be held on 25 September 2024.Powered by Capital Market - Live

Net profit of Healthcare Global Enterprises rose 58.74% to Rs 12.08 crore in the quarter ended June 2024 as against Rs 7.61 crore during the previous quarter ended June 2023. Sales rose 14.14% to Rs 524.69 crore in the quarter ended June 2024 as against Rs 459.71 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales524.69459.71 14 OPM %17.3216.16 - PBDT66.0051.53 28 PBT18.9910.52 81 NP12.087.61 59 Powered by Capital Market - Live